Podcasts about cardiovascular outcomes

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.     Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) - NEJM 2.     Diabetes and Anemia – Diabetes Care 3.     Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials – Diabetes Care 4.     Cardiovascular and Kidney Outcomes and Mortality With Long- Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials – Diabetes Care 5.     Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes - NEJM   For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Sex Differences in Achieved Diastolic Blood Pressure and Cardiovascular Outcomes in Elderly Patients With Hypertension.

Commentary by Dr. Jafar Al-Mondhiry.

In this podcast, Dr. Valentin Fuster discusses a pivotal study on the benefits of early acetamide initiation combined with statins after a myocardial infarction, showing improved cardiovascular outcomes. The study's findings suggest that early combination therapy reduces the risk of major cardiovascular events, urging healthcare pathways to adopt this approach as standard practice for better patient outcomes.

Trials from the 2025 American College of Cardiology scientific sessions, including the WARRIOR, PROTECT TAVI, DAPATAVI, and SOUL are reviewed by John Mandrola, MD This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Thank you Comments II WARRIOR Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD Keep Fighting INOCA After Neutral WARRIOR Trial https://www.medscape.com/viewarticle/keep-fighting-inoca-after-neutral-warrior-trial-2025a10007uf III Cerebral Embolic Protection in TAVI PROTECT TAVI https://www.nejm.org/doi/full/10.1056/NEJMoa2415120 PROTECTED TAVR https://www.nejm.org/doi/full/10.1056/NEJMoa2204961 Instrumental Variables in Randomized Trials https://evidence.nejm.org/doi/10.1056/EVIDctw2400204 IV  DAPATAVI SGLT2 Inhibitors Progressing to New Standard After TAVI https://www.medscape.com/viewarticle/sglt2-inhibitors-progressing-new-standard-after-tavi-2025a100081y Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation https://www.nejm.org/doi/full/10.1056/NEJMoa2500366 V SOUL Study of Oral Semaglutide and CV outcomes in Diabetes Oral GLP-1 Receptor Agonist Reduces CV Risk https://www.medscape.com/viewarticle/oral-glp-1-receptor-antagonist-reduces-cv-risk-2025a10007kr Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa2501006 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Send us a textEpisode 112 - Top Papers from the 2025 American College of Cardiology (ACC) SessionWelcome back Rounds Table Listeners! We are back today with a special Rapid Fire Podcast! This week, Drs. Mike and John Fralick discuss top papers from the 2025 American College of Cardiology (ACC) Annual Scientific Session. Hot off the presses, here we go!Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism (0:00 - 5:55)Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation (DapaTAVI) (5:56 - 9:51)Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (9:52 - 14:04)Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE) (14:05 - 18:36)The Good Stuff:The Studio TV series on Apple (18:37 - 19:11)Cardiology Trial Files (19:12 - 20:40)Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePodsSupport the show

Send us a textWelcome back Rounds Table Listeners! We are back today with a special Rapid Fire Podcast! This week, Drs. Mike and John Fralick discuss top papers from the 2025  American College of Cardiology (ACC) Annual Scientific Session. Hot off the presses, here we go!Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism (0:00 - 5:55)Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation (DapaTAVI) (5:56 - 9:51)Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (9:52 - 14:04)Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE) (14:05 - 18:36)The Good Stuff:The Studio TV series on Apple (18:37 - 19:11)Cardiology Trial Files (19:12 - 20:40)Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Send us a textWelcome back Rounds Table Listeners! In this throwback episode, Drs. Mike and John Fralick chat about five important research studies published in 2023:Hydrocortisone in Severe Community-Acquired Pneumonia (0:00 – 5:39).Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes (5:40 – 8:48).Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (8:49 – 12:29).Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection (12:30 – 17:49).Early versus Later Anticoagulation for Stroke with Atrial Fibrillation (17:50 – 23:38).And for the Good Stuff:The Beckham docuseries on Netflix (23:39 – 24:15)Upside Drinks (24:16 – 26:04).Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Section 1: Introduction (0:00 - 5:30) Dr. Valentin Fuster introduces a special issue on Prevention, covering societal and individual prevention aspects and key cardiovascular risk factors. He highlights issues like medication adherence, obesity, and the need for better education and healthcare systems. Section 2: Prevention in Society (5:30 - 35:30) Adherence to Medications The PURE trial shows low medication adherence (31% at follow-up) across 17 countries, despite technological advancements in diagnostics. Barriers include low health literacy and inadequate healthcare systems. Social Determinants of Health Social deprivation leads to worse cardiovascular outcomes, especially among sexual minorities in the U.S. The editorial calls for more equitable healthcare access and anti-stigma efforts. Environmental Factors: Aircraft Noise Higher aircraft noise exposure is linked to worse heart health, urging noise reduction policies for vulnerable populations. Section 3: Prevention in Individuals (35:30 - 55:30) Sedentary Behavior Even with exercise, high sedentary time (over 10.6 hours a day) increases cardiovascular risk. Reducing sedentary time can significantly lower heart disease risk. Intensive Lifestyle Interventions for Diabetes Weight loss and lifestyle changes improve cardiac biomarkers and reduce cardiovascular risk in type 2 diabetes patients. Section 4: Risk Factor Impacts (55:30 - 1:10:00) Hyperlipidemia & Obesity Hyperlipidemia and obesity management, including medications like semaglutide, play key roles in preventing cardiovascular disease. The 2024 ESC hypertension guidelines are also crucial in risk reduction.

Section 1: Introduction (0:00 - 5:30) Dr. Valentin Fuster introduces a special issue on Prevention, covering societal and individual prevention aspects and key cardiovascular risk factors. He highlights issues like medication adherence, obesity, and the need for better education and healthcare systems. Section 2: Prevention in Society (5:30 - 35:30) Adherence to Medications The PURE trial shows low medication adherence (31% at follow-up) across 17 countries, despite technological advancements in diagnostics. Barriers include low health literacy and inadequate healthcare systems. Social Determinants of Health Social deprivation leads to worse cardiovascular outcomes, especially among sexual minorities in the U.S. The editorial calls for more equitable healthcare access and anti-stigma efforts. Environmental Factors: Aircraft Noise Higher aircraft noise exposure is linked to worse heart health, urging noise reduction policies for vulnerable populations. Section 3: Prevention in Individuals (35:30 - 55:30) Sedentary Behavior Even with exercise, high sedentary time (over 10.6 hours a day) increases cardiovascular risk. Reducing sedentary time can significantly lower heart disease risk. Intensive Lifestyle Interventions for Diabetes Weight loss and lifestyle changes improve cardiac biomarkers and reduce cardiovascular risk in type 2 diabetes patients. Section 4: Risk Factor Impacts (55:30 - 1:10:00) Hyperlipidemia & Obesity Hyperlipidemia and obesity management, including medications like semaglutide, play key roles in preventing cardiovascular disease. The 2024 ESC hypertension guidelines are also crucial in risk reduction.

Eileen Egan, DNP, FNP-C, BC-ADM, CDCES, FADCES joins The Huddle to share her expertise about the interplay between weight and glycemic management in people with Type 2 diabetes, the importance of meeting glycemic and weight goals early after a Type 2 diabetes diagnosis, as well as best practices for helping people stay motivated and engaged. This episode was made possible with support from Lilly, A Medicine Company. Learn more about this topic in this accompanying patient/client handout (support for the development of this handout was provided by Lilly, A Medicine Company): adces_tipsheet_early_control2.pdf References:American Diabetes Association. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes- 2024. Diabetes Care, 47(1): S145-S157.Center for Disease Control and Prevention. Adult overweight and obesity. https://www.cdc.gov/obesity/basics/adult-defining.htmlDCCT/EDIC study research group. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care. 2016;39(5):686-693. Gregg E, Jakicic J, Blackburn G, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post hoc analysis of the Look AHEAD randomized clinical trial. Lancet Diabetes Endocrinol. 2016; 4(11): 913-921.Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases. Int J Mol Sci. 2021. 27;22(21):11629.Howard BV, Ruotolo G, Robbins DC. Obesity and dyslipidemia. Endocrinol Metab Clin North Am. 2003;32(4):855-867. Jin X, et al. Pathophysiology of obesity and its associated diseases. Acta Pharm Sin B. 2023;13(6):2403-2424.  Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2019;42(3):416-426.Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.Lancet Diabetes Endocrinol. 2019;7(5):344-355.Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022 Jan 22;399(10322):394-405. doi: 10.1016/S0140-6736(21)01919-X. Epub 2021 Sep 30. Erratum in: Lancet. 2022 Jan 22;399(10322):358. PMID: 34600604Rachel G. Miller, Trevor J. Orchard; Understanding Metabolic Memory: A Tale of Two Studies. Diabetes 1 March 2020; 69 (3): 291–299. https://doi.org/10.2337/db19-0514Ross, R., Neeland, I.J., Yamashita, S. et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol16, 177–189 (2020). https://doi.org/10.1038/s41574-019-0310-7Thom G, McIntosh A, Messow CM, et al. Weight loss-induced increase in fasting ghrelin concentration is a predictor of weight regain: Evidence from the Diabetes Remission Clinical Trial (DiRECT). Diabetes Obes Metab. 2021;(23):711-719.Tsai AG, Bessesen DH. Obesity. Ann Intern Med. 2019;170(5):ITC33-ITC48.Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-154.World Health Organization. Obesity. https://www.who.int/health-topics/obesity#tab=tab_1 Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

This week we review a recent large scale, multicenter adult congenital heart study on outcomes of HLHS Fontan patients versus other single RV Fontan patients. How do the two groups compare in regards to thromboembolic risk, risk for arrhythmia or risk for death and heart transplantation? Why might there be differences between these single RV patient groups? How can these results inform management? We speak with Assistant Professor of Medicine and Pediatrics at The Icahn School of Medicine at  Mount Sinai, ACHD expert Dr. Kali Hopkins. doi: 10.1161/JAHA.124.034757. Epub 2024 Nov 27

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances discusses a recently published original research paper on the association of automated breast arterial calcification score with cardiovascular outcomes and mortality.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances discusses a recently published original research paper on an association between systolic blood pressure time in target range indices and adverse cardiovascular outcomes.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances discusses a recently published original research paper on the impact of changes in depression on cardiovascular outcomes in patients with coronary heart disease.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances discusses a recently published original research paper on consequences of recurrent hyperkalemia on cardiovascular outcomes and mortality.

Howie and Harlan are joined by investor and entrepreneur Halle Tecco to discuss her work connecting the worlds of technology and healthcare, and her latest venture, which allows women to freeze their eggs for future use for free if they donate half of them to a couple in need. Harlan checks in from the annual meeting of the American Heart Association; Howie discusses his concerns about Robert F. Kennedy Jr.'s appointment as secretary of health and human services. Links: American Heart Association Meeting “Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure”   “Intensive Lifestyle Intervention, Cardiac Biomarkers, and Cardiovascular Outcomes in Diabetes: LookAHEAD Cardiac Biomarker Ancillary Study” “Accelerometer-Measured Sedentary Behavior and Risk of Future Cardiovascular Disease” Halle Tecco  Halle Tecco: Blog Halle Tecco: Investing in Digital Health Startups Course “This power couple bought bitcoin in 2013, and just donated all their gains to a cancer hospital” Rock Health Natalist Cofertility RFK Jr. “What to know about RFK Jr.'s views on food, vaccines, abortion, and the FDA” “How a Kennedy built an anti-vaccine juggernaut amid COVID-19” “With Trump coming into power, the NIH is in the crosshairs” “RFK Jr.'s Inside Job” “How RFK Jr.'s MAHA movement could shake up public health” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

JACC Associate Editor Muthiah Vaduganathan, MD speaks with author Ambarish Pandey, MD about the LookAHEAD trial published in JACC and presented at AHA. Among adults with T2D and overweight/obesity in the Look Action for Health in Diabetes (AHEAD) trial, an intensive lifestyle intervention targeting weight loss led to sustained reductions in hs-cTnT at 1- and 4-year follow-up, and a rise in NT-proBNP at 1 year that attenuated at 4 years. After accounting for baseline biomarker levels and baseline and changes in risk factors, longitudinal increase in NT-proBNP was associated with higher risk of ASCVD and incident HF. In contrast, increase in hs-cTnT was significantly associated with ASCVD but not incident HF.

JACC Associate Editor Marc P. Bonaca, MD, FACC, speaks with author Subodh Verma, MD, PhD, and A. Michael A. Lincoff, MD, FACC, about this brief report published in JACC and presented at AHA. Following CABG surgery there remains a markedly high risk of persistent ischemic events, heart failure, and mortality. Semaglutide consistently reduced all cardiovascular outcomes in this population.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on impact of guideline-directed statin prescriptions on cardiovascular outcomes by race in a real-world primary prevention cohort.

32nd ESC 2024: Cardiovascular Outcomes in Women

CME credits: 0.50 Valid until: 18-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/new-horizons-unraveling-novel-therapies-for-enhanced-cardiovascular-outcomes-in-patients-with-heart-failure/26966/ There are limited therapeutic options for patients with heart failure with mid-range or preserved ejection fraction (HFmrEF/HFpEF). Recently, new data were released on the efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists (MRAs) in patients with HFmrEF/HFpEF. What are the outcomes of the FINEARTS-HF trial with finerenone in this patient population, and what do these findings mean for clinical practice? Three cardiologists discuss the topic of novel therapies, with a focus on nonsteroidal MRAs, to improve cardiovascular outcomes in patients with HFmrEF/HFpEF. =

In this episode, Dr. Josh Mitchell reviews a significant study that explores the links between physical health markers, such as waist circumference and hand grip strength, and cardiovascular outcomes in men with prostate cancer undergoing androgen deprivation therapy. The findings indicate that increased waist circumference and decreased grip strength are associated with higher cardiovascular event risks, highlighting the need for targeted interventions like exercise in these patients and emphasizing the importance of further research in diverse populations.

Howie and Harlan are joined by Ania Jastreboff, a Yale endocrinologist and an expert on obesity medication, to talk about the remarkable range of diseases treated by drugs like Ozempic, Mounjaro, and Wegovy. Harlan discusses new Apple devices with the ability to detect sleep apnea and aid in hearing; Howie reports on outbreaks of polio in Pakistan, Afghanistan, and Gaza.  Links: Apple and Health “FDA clears Apple's sleep apnea detection feature for use. Here's how it works” FDA: “FDA Authorizes First Over-the-Counter Hearing Aid Software” “FDA approves some Apple AirPods to be used as hearing aids” National Council on Aging: Reasons for Low Hearing Loss Treatment Obesity Drugs “Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity” “An Obesity Drug Prevents Covid Deaths, Study Suggests” “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes” “The New Anti-Obesity Drugs: What You Should Know” Video: Oprah Winfrey and Ania Jastreboff, “What Exactly Is Obesity? A Yale Doctor Explains” “Obesogenic environments and obesity: a comment on ‘Are environmental area characteristics at birth associated with overweight and obesity in school-aged children? Findings from the SLOPE (Studying Lifecourse Obesity PrEdictors) population-based cohort in the south of England'” “Oprah Takes on Weight Stigma in the Ozempic Era” “Once-Weekly Semaglutide in Adults with Overweight or Obesity” Ania Jastreboff: “Tirzepatide Once Weekly for the Treatment of Obesity” Ania Jastreboff: “Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial” “Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity” “Obesity drug black market thrives online in S. Korea” “Novo Nordisk's Wegovy Weight-Loss Drug Gets Approval in China” “A Popular Weight Loss Drug Is Getting a Price Cut” Polio Poliovirus outbreak in New York State, August 2022: qualitative assessment of immediate public health responses and priorities for improving vaccine coverage CDC: Vaccine-Derived Poliovirus WHO: “Humanitarian pauses vital for critical polio vaccination campaign in the Gaza Strip” Howard Forman Discusses Polio in Gaza on TikTok CDC: Progress Toward Poliomyelitis Eradication—Pakistan, January 2023–June 2024 “Afghanistan risks polio outbreak as Taliban restricts women from delivering vaccines” “Polio eradication: the CIA and their unintended victims” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

Iaaaaaaaaago Jorge, Marcela Belleza e Nathalie Santana conversam sobre as últimas atualizações no tratamento da obesidade em três partes: o que é obesidade controlada? quais são as drogas novas? quais são os efeitos adversos? Use o cupom TDC2024 para assinar o HITT do Medcof e ganhe um cupom de 6 meses gratuitos do Guia TdC! https://hiit.grupomedcof.com.br Referências: 1. Chuang MH, Chen JY, Wang HY, Jiang ZH, Wu VC. Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes. JAMA Netw Open. 2024;7(8):e2427258. Published 2024 Aug 1. doi:10.1001/jamanetworkopen.2024.27258 2. Coutinho W, Halpern B. Pharmacotherapy for obesity: moving towards efficacy improvement. Diabetol Metab Syndr. 2024;16(1):6. Published 2024 Jan 3. doi:10.1186/s13098-023-01233-4 3. Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA. Published online July 22, 2024. doi:10.1001/jama.2024.10816 4. Halpern B, Mancini MC, de Melo ME, et al. Proposal of an obesity classification based on weight history: an official document by the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society for the Study of  5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038 6. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972 7. Li JR, Cao J, Wei J, Geng W. Case Report: Semaglutide-associated depression: a report of two cases. Front Psychiatry. 2023;14:1238353. Published 2023 Aug 29. doi:10.3389/fpsyt.2023.1238353 8. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 9. Obesity and Metabolic Syndrome (ABESO). Arch Endocrinol Metab. 2022;66(2):139-151. doi:10.20945/2359-3997000000465 10. Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. Published online July 8, 2024. doi:10.1001/jamainternmed.2024.2525 11. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population [published correction appears in Nat Commun. 2024 Jun 18;15(1):5177. doi: 10.1038/s41467-024-49655-6]. Nat Commun. 2024;15(1):4548. Published 2024 May 28. doi:10.1038/s41467-024-48780-6 12. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30(1):168-176. doi:10.1038/s41591-023-02672-2

JACC: CardioOncology Editor-in-chief, Bonnie Ky, MD, MSCE, FACC and Yichao Xiao, MD discuss the study design, findings, future research questions and the potential clinical impact on the management of blood pressure in cancer survivors.

JACC: CardioOncology Editor-in-chief, Bonnie Ky, MD, MSCE, FACC and Tom Marwick, MBBS, PhD, MPH discuss the study design, findings and the use of strain surveillance during chemotherapy to improve cardiovascular outcomes.

In this episode, Dr. Valentin Fuster reviews a groundbreaking study comparing metabolic surgery to traditional care for patients with obesity and obstructive sleep apnea. The research shows that metabolic surgery significantly lowers the risk of major cardiovascular events and mortality, highlighting the need for a multifaceted approach to treating these interlinked conditions.

In the September 10, 2024, issue of JACC, the study by Dr. Doron Seeker and colleagues investigates alirocumab's impact on cardiovascular outcomes related to triglyceride levels. Despite effectively lowering LDL cholesterol, alirocumab did not show significant clinical benefit through triglyceride reduction, suggesting that its efficacy may be limited in addressing cardiovascular risk associated with elevated triglycerides.

Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research that was presented at the 2024 European Society of Cardiology annual meeting. Visit NEJM.org to read the latest research.

Welcome to the latest episode of Medmastery's Cardiology Digest, where In less than 15 minutes we'll get you up to date on breakthrough studies and advancements in cardiology that can impact your clinical practice! STUDY #1: Brace yourself for insights into a study that evaluated rapid uptitration of evidence-based therapies for heart failure. Join us as we dissect the feasibility, resource demands, and patient implications?  Biegus, J, Mebazaa, A, Davison, B, et al. 2024. Effects of rapid uptitration of neurohormonal blockade on effective, sustainable decongestion and outcomes in STRONG-HF. J Am Coll Cardiol. 4: 323–336.  (https://doi.org/10.1016/j.jacc.2024.04.055) STUDY #2: Next, we examine a recent paper that challenges hospital-centric treatment paradigms for acute pulmonary embolism. Discover how some low-risk patients could benefit from home treatment, and what conditions are essential to ensure their safety and effective care.  Luijten, D, Douillet, D, Luijken, K, et al. 2024. Safety of treating acute pulmonary embolism at home: An individual patient data meta-analysis. Eur Heart J. 32: 2933–2950. (https://doi.org/10.1093/eurheartj/ehae378) STUDY #3: Finally, we dive into a large cohort study looking at bariatric surgery in obese patients with obstructive sleep apnea, and see whether losing weight actually had a significant impact on cardiovascular outcomes. Aminian, A, Wang, L, Al Jabri, A, et al. 2024. Adverse cardiovascular outcomes in patients with obstructive sleep apnea and obesity: Metabolic surgery vs usual care. J Am Coll Cardiol. Published online. (https://doi.org/10.1016/j.jacc.2024.06.008) This episode promises to be packed with actionable insights on this thought-provoking cardiology research. Don't miss out—press play and enrich your practice today!  Learn more with Medmastery's courses: Chest X-ray Essentials (7 CME) Chest X-ray Essentials Workshop (1 CME) Get a Basic or Pro account, or, get a Trial account. Show notes: Visit us at  https://www.medmastery.com/podcasts/cardiology-podcast.

In the September 3, 2024, JACC issue, a major study evaluates the cardiovascular outcomes of second-line antihyperglycemic agents in type 2 diabetes, comparing SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas. The research reveals that SGLT2 inhibitors and GLP-1 receptor agonists offer superior cardiovascular protection over the other agents, highlighting their importance for patients with cardiovascular conditions.

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.     Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes 2.     Association between the Burden of Microvascular Disease and Cardiorespiratory Fitness among Adults with Type 2 Diabetes 3.     Association of metabolic syndrome with neuroimaging and cognitive outcomes 4.     Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity 5.     Semaglutide and Cardiovascular Outcomes by Baseline HbA and Change in HbA in SELECT   For more information about each of ADA's science and medical journals, please visit www.diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health

A new study finds an increased risk of major adverse cardiovascular events in adulthood after incident diagnosis of hypertension in childhood. Stephen Daniels, MD, PhD, of the University of Colorado discusses hypertension screening and treatment of children and adolescents with JAMA Pediatrics Editor in Chief Dimitri Christakis, MD, MPH, and JAMA Pediatrics Associate Editor Alison Galbraith, MD, MPH. Related Content: Long-Term Cardiovascular Outcomes in Children and Adolescents With Hypertension

Welcome back Rounds Table Listeners!In this throwback episode, Drs. Mike and John Fralick discuss the use of semaglutide in patients with obesity without diabetes and changes in renal function after starting dapagliflozin in patients with heart failure. Check it out below!Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial (0:00 – 09:40).Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (09:40 – 19:24).And for the Good Stuff:How Ozempic and Weight Loss Drugs Are Reshaping Denmark's Economy (19:24 – 19:58).How a Canadian scientist and a venomous lizard helped pave the way for Ozempic (19:58 – 23:36).Questions? Comments? Feedback? We'd love to hear from you! @roundstable

The Filtrate:Joel TopfSwapnil HiremathJosh WaitzmanNayan AroraSophia AmbrusoWith Special Guest:Brendon Neuen Super smart guy and clinical trialistVlado Perkovic Lead author of FLOW and friend of NephJCEditor Joel TopfShow NotesThe manuscript (NEJM): Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesThe acronym FLOW from the title: evaluate renal Function with semagLutide Once Weekly (Twitter)Joel wrote a blog post prior to the FLOW publication to try to set the table: Peeking Inside Schrödinger's BoxBrendon's Neuen's tweet about total versus chronic slope (X | Twitter)Modification of Association of Cystatin C With Kidney and Cardiovascular Outcomes by Obesity (Science Direct)Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials (PubMed)The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis (Frontiers in Pharmacology)Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials (PubMed)Proteinuria Thresholds Are Irrational: A Call for Proteinuria Indexing (Nephron Clinical Practice)Frank Harrel on why the NNT sucks (data methods)Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells (PubMed)Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance (PubMed)Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial (PubMed)Doctors are like the pyromaniac fireman (PBFluids)Suggest topics for NephMadness (Twitter)Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE) (PubMed)Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial (PubMed)Spitzer's involvement in revolutionizing nephrology is part of this lecture I did at the University of Nebraska Diabetes Symposium. (Dropbox: Start on slide 29)Spitzer Resigns, Citing Personal Failings (New York Times)Tubular Secretions Swap: Dumb Money on NetFlix (Wikipedia)Josh: Hiking Zion National Park (National Park Service)Sophia: Lost in Space 2018 TV series on NetFlix (Wikipedia)Nayan: Pelican Hill resort (Website)Joel: BodkinNephJC Summer Book Club: Covenant of Water by Abraham Verghese (Amazon)

Commentary by Dr Milind Desai

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/MVU865. CME credit will be available until April 25, 2025.Exploring the Evidence: Improving Cardiovascular Outcomes and the Role of Weight Loss Pharmacotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/MVU865. CME credit will be available until April 25, 2025.Exploring the Evidence: Improving Cardiovascular Outcomes and the Role of Weight Loss Pharmacotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/MVU865. CME credit will be available until April 25, 2025.Exploring the Evidence: Improving Cardiovascular Outcomes and the Role of Weight Loss Pharmacotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/MVU865. CME credit will be available until April 25, 2025.Exploring the Evidence: Improving Cardiovascular Outcomes and the Role of Weight Loss Pharmacotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/MVU865. CME credit will be available until April 25, 2025.Exploring the Evidence: Improving Cardiovascular Outcomes and the Role of Weight Loss Pharmacotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/MVU865. CME credit will be available until April 25, 2025.Exploring the Evidence: Improving Cardiovascular Outcomes and the Role of Weight Loss Pharmacotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

CSL112 (Apolipoprotein A-I) Infusions And Cardiovascular Outcomes In Patients With Acute Myocardial Infarction (ApoA-I Event Reducing In Ischemic Syndromes II (AEGIS-II) Trial): Primary Trial Results

Infarction ACC.24: AEGIS-II Trial

Commentary by Dr. Candice Silversides

In part one we looked at the staggering conflicts of interest and issues with the efficacy in the Semaglutide 2.4 (Wegovy) cardiovascular trial (Semaglutide and Cardiovascular Outcomes in Ob*sity* without Diabetes DOI: 10.1056/NEJMoa2307563) especially as compared to the deeply misleading claims in Novo Nordisk's “company announcement” publicity stunt prior to publication.Today we're going to dig deeper into the data, what there is of it, anyway. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Lead Story: Association of Cannabis Use With Cardiovascular Outcomes Among US Adults  Journal of the American Heart Association Cannabis use has increased in the US and perceived harmfulness has decreased, but there is evidence to suggest that cannabis use may increase risk of cardiovascular disease. In this study, the authors utilized the Brief Risk Factor Surveillance System survey to assess association between cannabis use and cardiovascular disease. In a multivariate analysis, they found an association between daily cannabis use and myocardial infarction (MI) (aOR=1.25) and stroke (aOR=1.42). Among adults who had never smoked cigarettes, the association was even greater for MI (aOR=1.49) and stroke (aOR=2.16). While additional research is needed, these findings suggest cannabis may be a risk for cardiovascular disease, independent of cigarette use. Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

A new class of medicines has transformed the treatment of obesity -- Wegovy and Ozempic have become household names. While we discussed these GLP-1 medicines on an episode of Beyond the Abstract less than a year ago, the field has progressed so quickly we thought it was already time to review many of these recent developments. In today's episode, Derek and Dan first discuss improved versions of these medicines on the horizon for the treatment of obesity. Derek and Dan then talk about how these medicines are being studied to treat a wide range of diseases outside of obesity, ranging from cardiovascular disease to substance use disorder. Articles discussedJastreboff et al 2023 NEJM, Triple-Hormone Receptor Agonist Retatrutide for Obesity -- A Phase 2 Trial (https://www.nejm.org/doi/full/10.1056/NEJMoa2301972)Wharton et al 2023 NEJM, Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (https://www.nejm.org/doi/full/10.1056/NEJMoa2302392)Lincoff et al 2023 NEJM, Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (https://www.nejm.org/doi/full/10.1056/NEJMoa2307563)Kosiborod et al 2023 NEJM, Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (https://www.nejm.org/doi/full/10.1056/NEJMoa2306963)The information presented here is not medical advice. Consult your physician for any questions regarding your personal health.

In this week's Parallax, Dr Ankur Kalra welcomes back Dr Sukhjinder Nijjer for their much-anticipated annual review of advancements in cardiovascular medicine that defined the year 2023. Dr Nijjer, a Consultant Cardiologist in the UK, serves as the President of the Royal Society of Medicine and is an Honorary Senior Clinical Lecturer at Imperial College London. Drs Kalra and Nijjer share their perspectives and experiences, offering valuable insights, practical tips and considerations when interpreting this year's most impactful trials: • ORBITA-2 (AHA Scientific Sessions): PCI for stable angina • FIRE (ESC Congress): Functional versus culprit-only revascularization in elderly patients with myocardial infarction and multivessel disease • DAPA-MI (AHA Scientific Sessions): SGLT2i in MI without diabetes or heart failure • ILUMIEN IV (ESC Congress): OCT vs angiography-guided PCI • OCTOBER (ESC Congress): OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions • ARTESIA (ESC Congress): Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation • SELECT (AHA Scientific Sessions): Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes What are the most impactful cardiovascular trials of 2023? How do Dr Kalra and Dr Nijjer integrate the latest information into their daily practices?